News
Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...
6d
Health and Me on MSNWHO Recommends New HIV Twice-Yearly Shot Amid Fund Cuts; What Are The Big Challenges The Drug Faces?WHO has officially recommended twice-yearly injectable lenacapavir for HIV prevention, marking a major shift in global HIV ...
6d
Africanews on MSNTrump Administration's funding cuts jeopardize HIV research in South AfricaAt the University of the Witwatersrand, scientists are developing HIV vaccines that could help change the course of the ...
South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research ...
Cuts to U.S. foreign aid will endanger HIV treatment and prevention services globally and are likely to reverse decades of ...
During his 36-year career at Cancer Center, Michael Emerman, PhD, made fundamental discoveries about HIV, the retrovirus that ...
Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...
The field of HIV treatment has witnessed a significant transformation since the mid-1990s with the introduction of ...
Clinicians will need a crash course in what AIDS-related infections look like, she said; young doctors will not have seen them because South Africa’s H.I.V. program has been so effective over ...
Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an antiviral drug for HIV prevention based on his findings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results